Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics


Emergent Biosolutions, Inc. (EBS)

Today's Latest Price: $79.67 USD

2.99 (-3.62%)

Updated Nov 23 6:40pm

Add EBS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

EBS Stock Summary

  • EBS has a market capitalization of $4,380,908,830 -- more than approximately 74.51% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Emergent BioSolutions Inc is reporting a growth rate of 448.56%; that's higher than 96.73% of US stocks.
  • Revenue growth over the past 12 months for Emergent BioSolutions Inc comes in at 31.13%, a number that bests 84.84% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Emergent BioSolutions Inc are ACLS, FORM, NVMI, SRNE, and ERII.
  • Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.

EBS Stock Price Chart Interactive Chart >

Price chart for EBS

EBS Price/Volume Stats

Current price $79.67 52-week high $137.61
Prev. close $82.66 52-week low $46.37
Day low $77.73 Volume 690,500
Day high $83.77 Avg. volume 645,185
50-day MA $96.50 Dividend yield N/A
200-day MA $86.20 Market Cap 4.22B

Emergent Biosolutions, Inc. (EBS) Company Bio


Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.

EBS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$79.67$124.34 50%

Below please find a table outlining a discounted cash flow forecast for EBS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Emergent BioSolutions Inc ranked in the 56th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 51%. In terms of the factors that were most noteworthy in this DCF analysis for EBS, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 8.13 -- which is good for besting 65.77% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • Emergent BioSolutions Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.74% of tickers in our DCF set.
  • Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 19 -- greater than 76.27% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%47%
1%49%
2%50%
3%52%
4%53%
5%55%

HRC, MCK, DXCM, PRAH, and ACIU can be thought of as valuation peers to EBS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


EBS Latest News Stream


Event/Time News Detail
Loading, please wait...

EBS Latest Social Stream


Loading social stream, please wait...

View Full EBS Social Stream

Latest EBS News From Around the Web

Below are the latest news stories about Emergent BioSolutions Inc that investors may wish to consider to help them evaluate EBS as an investment opportunity.

Insider Sells Emergent BioSolutions Stock

Shares of Emergent BioSolutions Inc (NYSE:EBS) fell by 3.5% from the previous closing price. Harsanyi Zsolt filed a Form 4 with the SEC on Tuesday, August …

Benzinga | August 18, 2020

Uma Sharma, PhD of MMS Holdings and Ron Perry of Emergent BioSolutions Join MichBio Board of Directors

ANN ARBOR, Mich.--(BUSINESS WIRE)-- #bioindustry--MichBio welcomes Uma Sharma, PhD Chief Scientific Officer at MMS Holdings and Ron Perry Vice President and General Manager at Emergent BioSolutions to the Board of Directors. Uma Sharma, PhD was appointed in mid-August to complete a term expiring in December 2021. As the CSO of MMS Holdings, she is a hands-on leader focused on guiding sponsors on clinical strategy and colleagues through an inclusive leadership model. Dr. Sharma has a personal philosophy of pay

Business Wire | August 18, 2020

FDA OKs shelf life extension for Emergent Bio's Narcan

The FDA has approved Emergent BioSolutions' (EBS) shelf life extension of NARCAN (naloxone HCl) Nasal Spray from 24 months to 36 months.Narcan Nasal Spray was the first intranasal form of naloxone approved for the emergency treatment of known or suspected opioid overdose....

Seeking Alpha | August 17, 2020

COVID-19 treatment: Biological E to manufacture substance needed in J&J's vaccine

J&J aims to produce more than 1 billion doses of its vaccine candidate, and has struck a similar deal with U.S.-based Emergent BioSolutions Inc to boost manufacturing

Business Today | August 13, 2020

The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDA...

Benzinga | August 7, 2020

Read More 'EBS' Stories Here

EBS Price Returns

1-mo -17.11%
3-mo -35.61%
6-mo -2.82%
1-year 46.05%
3-year 91.15%
5-year 107.96%
YTD 47.67%
2019 -8.99%
2018 27.57%
2017 41.50%
2016 -17.92%
2015 46.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8424 seconds.